Journal article
Evaluation of naturally occurring IgG anti-Vi antibody titers as predictors and correlates of typhoid fever in Dhaka, Bangladesh
- Abstract:
- Background: When delivered through vaccination Vi-polysaccharide antigen of Salmonella enterica serotype Typhi protects against typhoid by inducing IgG anti-Vi antibodies. We aimed to determine whether the presence of antibodies following natural infection is associated with a lower incidence of typhoid fever in endemic regions. Methods: We analyzed data from a cohort study of typhoid fever conducted in Dhaka, Bangladesh. Plasma IgG anti-Vi antibodies were measured using a standard enzyme-linked immunosorbent assay in random serosurveys of a population that had not previously received typhoid vaccination. Participants were followed for up to 20 months for culture-confirmed typhoid fever. The receiver operating characteristic (ROC) curve and Cox proportional hazard models were used to evaluate the associations between antibody levels and typhoid risk. Results: The ROC analysis revealed that IgG anti-Vi antibody titers were predictive of typhoid risk among the 8,261 serosurvey participants (area under the curve: 0·63; 95% confidence interval (CI): 0·58─0·67). Detection of any antibodies was associated with a lower risk of typhoid in crude analyses (hazard ratio (HR): 0·13; 95% CI: 0·03─0·52), though this association declined after adjustment (HR: 0·32; 95% CI: 0·07─1·40). A positive correlation was observed between IgG anti-Vi titers and age (correlation coefficient 0·35; p < 0·001), with a stepwise increase in detectable antibodies by age, ranging from 12·0% (280/2,333) in children under 5 years to 54·2% (463/854) in individuals 50 years and older (p < 0·001). Conclusions: In typhoid-endemic populations, IgG anti-Vi antibodies may indicate natural immunity to typhoid. The increasing seroprevalence with age suggests that these antibodies could serve as markers of cumulative past typhoid infections. Future research should explore these possibilities. Clinical trial number: Not applicable.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.1186/s12879-025-10548-8
Authors
- Publisher:
- BioMed Central
- Journal:
- BMC Infectious Diseases More from this journal
- Volume:
- 25
- Issue:
- 1
- Article number:
- 149
- Publication date:
- 2025-01-31
- Acceptance date:
- 2025-01-23
- DOI:
- EISSN:
-
1471-2334
- Language:
-
English
- Keywords:
- Pubs id:
-
2082788
- Local pid:
-
pubs:2082788
- Source identifiers:
-
2647160
- Deposit date:
-
2025-02-01
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record